1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Psoriasis Drugs Market Forecasts 2016-2026

Psoriasis Drugs Market Forecasts 2016-2026

  • June 2016
  • 170 pages
  • ID: 4031803
  • Format: PDF
  • By Visiongain

Summary

Table of Contents

Report Details
Psoriasis Drugs – Your Guide to R&D, Opportunities and Potential Revenues
What does the future hold for treating psoriasis? Visiongain’s new report gives you multilevel revenue forecasts from 2016, helping you stay ahead in data. There you see financial results, R&D trends, opportunities and potential revenues.

In our study you examine predicted sales to 2026 at overall world market, submarket, product and national level. You also assess technologies, competitive forces and expected products. That work’s purpose is to help you avoid falling behind in knowledge, missing business or losing influence.

So read on now to explore that industry and discover what its future market could be worth. See how our investigation can benefit your work.

Forecasts from 2016 to 2026 and other analyses to help you harness opportunities
Why miss data you need? Why struggle to find it? Instead let our analysis guide you through the psoriasis drug market's present and future. That understanding could bring you quicker, easier results, also benefiting your influence and reputation for business insight.

Besides revenue forecasting to 2026, our new work shows you recent results, growth rates and market shares. There you discover original analysis, seeing commercial outlooks and developments (R&D). In our 169 page study you gain 74 tables and 63 charts to benefit your research, analyses, plans, decisions and presentations.

The following sections outline what you get in our updated investigation.

Sales predictions for the world market and submarkets
What is that industry’s potential? Discover in our report overall world revenue to 2026 for psoriasis-treating medicines. First you see individual revenue forecasts to 2026 for three main submarkets at world level:
- Biological drugs
- Topical treatments
- Small-molecule systemic therapies.

How will those segments’ revenues expand? Which classes of treatment will generate most sales? There you assess prospects for revenue growth, seeing where you can gain, assessing how that industry will compete and develop.

You find revenue predictions by product, too, seeing from 2016 how they can succeed.

Revenue predictions for 13 products to 2026 – discover what their futures hold
How will individual drugs perform from 2016 to 2026 at world level? Our report forecasts revenues of established brands and medicines expected from 2016.

In our work you assess 13 drugs, including these brands:
- Humira (adalimumab)
- Stelara (ustekinumab)
- Enbrel (etanercept)
- Remicade (infliximab)
- Otezla (apremilast)

There you discover how high sales can go, to 2026, finding drugs and years with highest predicted growth and revenues. You also examine trends and competition. You see what is happening, understanding challenges, progress, competitors and opportunities.

You find geographical revenue predictions too.

National markets – where will highest revenues and growth occur?
In developed and developing countries, opportunities in psoriasis treatment will occur from 2016. You see where and how pharma companies can develop and gain.

Our analyses show individual revenue forecasts to 2026 for these 11 national markets:
- US and Japan
- France, Germany, Italy, Spain and UK
- Brazil, Russia, India and China.

There you find countries with highest revenues and potential sales growth. You assess that technology’s future, seeing progress and finding what it means, including emerging trends for those skin disorder treatments.

Events affecting developers, producers and sellers – issues shaping that industry
Our report explains forces affecting that industry and market from 2016, including these influences:
- Research and development, including monoclonal antibodies, IL-12, IL-17, IL-23, PDE4, TNF, JAK and T-cell inhibition, and histamine receptor antagonism
- Prevalence of that skin disease, as well as issues for patients and healthcare providers – assess treatment needs
- Competition from generic drugs, biosimilars and new biologics
- Companies specialising in dermatology and autoimmune disorders – explore capabilities and emerging trends to treat psoriasis
- Advances in drug delivery to benefit companies, patients and payers, including lotion, ointment and foam.

In our survey you explore political, economic, social and technological questions, assessing outlooks for business. You also examine that pharmaceutical segment’s strengths, weaknesses, opportunities and threats.

That way you discover what the present and future hold, seeing what is possible for those drug developers, producers and marketers. Stay ahead in knowledge.

Companies leading that industry and our overall revenue prediction for 2020
From 2016, treatments for psoriasis hold potential for investments, medical advances and higher revenues. Our work predicts the overall world market for psoriasis medicines will reach $11.4bn in 2020, with further expansion to 2026.

See what is possible there – the expected gains. Our report shows you what technologies and firms hold greatest potential. You explore activities of these companies, among others:
- Johnson & Johnson
- AbbVie
- Amgen
- Pfizer
- Novartis
- Celgene
- LEO Pharma.

Our analysis shows you participants’ results, capabilities, developments and outlooks. R&D in that industry is strong. From 2016 the psoriasis market holds many opportunities for revenue growth. Our work explains that potential, helping you stay ahead in knowledge.

Main ways Psoriasis Drugs Market Forecasts 2016-2026 helps your work
In particular our new investigation gives you these advantages to benefit your research, analyses, decisions, proposals and presentations:
- Revenues to 2026 at world level, with forecasting of 3 submarkets and 13 products – assess prospects for investments and sales growth
- Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia – investigate leading countries for revenues and expected sales
- Forces driving and restraining that industry’s expansion – discover what influences revenue gain, finding trends, developments and opportunities
- Prospects for established competitors and rising companies – explore companies’ portfolios, results, R&D and outlooks for future success.

Information found nowhere else: see how you can gain – why miss out?
Our investigation gives you independent analysis. There you gain business intelligence found only in our work, finding where opportunities for revenue expansion exist.

See in our work how you could benefit your research, analysis and decisions. Explore progress and possibilities. Also find how you could save time and benefit your authority on those drugs, helping your reputation for commercial insight.

Medicines for psoriasis – get revenue predictions now, seeing what the future holds
Our new report is for everyone investigating drugs for inflammation and skin disorders. In our survey you explore revenue forecasts to 2026, with discussions and other data. Avoid missing out in knowledge – instead please get our report here now.

Please note: This report is accessed through a password system. Single user (non-printable) and departmental licenses expires after 12 month period.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2019

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica - Pipeline Review, H2 2019, provides an overview ...

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) ...

Ischemia Reperfusion Injury - Pipeline Review, H2 2019

Ischemia Reperfusion Injury - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Ischemia Reperfusion Injury - Pipeline Review, H2 2019SummaryPharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2019, provides an overview of the Ischemia ...


ref:plp2016

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on